METHOD FOR DETECTING CORONARY ENDOTHELIAL DYSFUNCTION AND EARLY ATHEROSCLEROSIS

• US 20080058642A1
• Filed: 08/31/2007
• Published: 03/06/2008
• Est. Priority Date: 09/05/2006
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: GOULD, K. Lance
• Application Number:
  US11/848,981
• Publication Number:
  US 20080058642A1
• Time in Patent Office: Days
• US Class Current: 600/436
• CPC Class Codes: A61B 5/02007 Evaluating blood vessel condition, e.g. elasticity, compliance
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 6/037 Emission tomography
• CPC Class Codes: A61B 6/503 for diagnosis of the heart
• CPC Class Codes: A61B 6/507 for determination of haemodynamic parameters, e.g. perfusion CT
• CPC Class Codes: A61B 6/508 for non-human patients

Abstract

A method of detecting endothelin receptor A mediated coronary microvascular endothelial dysfunction in an asymptomatic subject is disclosed. The method comprises obtaining sets of noninvasive cardiac PET perfusion images of the subject before and after administration of selective endothelin receptor A (ET_A receptor) antagonist. The images are analyzed, including application of applying Markovian homogeneity analysis, and the results are compared to detect improvement, or lack of improvement, of myocardial perfusion homogeneity in the subject. A result of improved myocardial perfusion homogeneity after administration of the antagonist indicates the presence of ET_A receptor-mediated microvascular endothelial dysfunction in the subject and indicates therapeutic treatment to improve endothelial function and/or to reduce coronary artery disease risk factors.

Claims

1. A method of detecting endothelin receptor A mediated coronary microvascular endothelial dysfunction in an asymptomatic subject, comprising:

(a) obtaining a first set of noninvasive cardiac PT perfusion images of the subject;

(b) analyzing the cardiac PET perfusion images obtained in step (a), wherein said analyzing comprises applying Markovian homogeneity analysis to said first set of images, to yield a first result comprising an initial myocardial perfusion homogeneity index;

(c) administering at least one selective endothelin receptor A antagonist to said subject;

(d) obtaining a second set of noninvasive cardiac PET perfusion images of said subject after said administration of said antagonist;

(e) analyzing the cardiac PET perfusion images obtained in step (d), wherein said analyzing comprises applying Markovian homogeneity analysis to said second set of images, to yield a second result comprising a second myocardial perfusion homogeneity index; and

(f) comparing said first and second results to detect improvement of myocardial perfusion homogeneity, or lack thereof, in said subject, wherein a result of improved myocardial perfusion homogeneity after administration of said antagonist indicates the presence of endothelin receptor A mediated coronary microvascular endothelial dysfunction in said subject.

2. The method of claim 1 wherein steps (a) and (d) further comprise administering a pharmacologic cardiac stress agent prior to obtaining said PET images.

3. The method of claim 2, wherein said cardiac stress agent comprises dipyridamole or adenosine, administered by intravenous infusion.

4. The method of claim 3 further comprising (g) comparing Markovian homogeneity analyses of cardiac PET perfusion images obtained with and without administration of said stress agent to said subject, wherein a result of improved myocardial perfusion homogeneity during pharmacologically induced cardiac stress is indicative of a stress perfusion abnormality.

5. The method of claim 1, wherein at least one endothelin receptor A antagonist is selected from the group consisting of Darusentan™

, Sitaxsentan™

, BQ123, BMS1822874, PD156707TTA101, 34-sulfatobastadin and BSF302146.

6. The method of claim 1, wherein improvement of myocardial perfusion homogeneity is quantitated at least in part by Markovian homogeneity analysis of cardiac PET perfusion images of the subject.

7. The method of claim 1, wherein the cardiac PET perfusion images comprise resting images.

8. The method of claim 1, wherein the subject, prior to administering the endothelin receptor A antagonist, exhibits a baseline resting myocardial perfusion homogeneity expressed as a Markovian homogeneity number that is outside about 2 standard deviation limits of a mean Markovian homogeneity number of a control group of normal healthy subjects.

9. The method of claim 8, wherein, following administration of the endothelin receptor A antagonist, an increase in the Markovian homogeneity number is obtained.

10. The method of claim 1, wherein the analysis of cardiac PET perfusion images comprises detection of regional perfusion defects, if any.

11. The method of claim 10, wherein, in (f), the comparison indicates a reduction in the size and/or severity of regional perfusion defects following administration of the endothelin receptor A antagonist.

12. The method of claim 1, wherein, in steps (b) and (e), the analysis of cardiac PET perfusion images comprises Markovian homogeneity analysis and either (i) observation of regional perfusion defects or (ii) measurement of a base to apex longitudinal perfusion gradient, or both (i) and (ii).

13. The method of claim 12, wherein the gradient is reduced following administration of the endothelin receptor A antagonist.

14. The method of claim 1, wherein in step (b) the analysis of the cardiac PET perfusion images reveals that an abnormal baseline resting myocardial perfusion homogeneity expressed as a Markovian homogeneity number that is lower than the mean Markovian homogeneity number of a control group of healthy subjects by a margin greater than about 2 standard deviation limits.

15. The method of claim 1 wherein, in step (f), a result of no improvement of myocardial perfusion homogeneity after said administration of said ET_A-receptor antagonist indicates the absence of ET_A-mediated microvascular endothelial dysfunction in said subject.

16. The method of claim 15, wherein said indication of an absence of endothelin receptor A mediated microvascular endothelial dysfunction in the subject is diagnostic of early coronary artery disease.

17. The method of claim 16, wherein the diagnosis of early coronary artery disease indicates therapeutic treatment of said subject to improve coronary endothelial function and/or to reduce coronary artery disease risk factors.

18. The method of claim 17 wherein one said therapeutic treatment comprises administration of a myocardial perfusion homogeneity enhancing amount of at least one endothelin receptor A antagonist.

19. The method of claim 1, wherein the subject has one or more risk factors associated with coronary disease.

20. The method of claim 1, wherein an indication of the presence of endothelin receptor A mediated microvascular endothelial dysfunction is diagnostic of existing coronary atherosclerosis and/or elevated risk of future coronary artery disease in the subject.